Literature DB >> 26507665

North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13.

Kent W Small1, Adam P DeLuca2, S Scott Whitmore2, Thomas Rosenberg3, Rosemary Silva-Garcia1, Nitin Udar1, Bernard Puech4, Charles A Garcia5, Thomas A Rice6, Gerald A Fishman7, Elise Héon8, James C Folk2, Luan M Streb2, Christine M Haas2, Luke A Wiley2, Todd E Scheetz2, John H Fingert2, Robert F Mullins2, Budd A Tucker2, Edwin M Stone9.   

Abstract

PURPOSE: To identify specific mutations causing North Carolina macular dystrophy (NCMD).
DESIGN: Whole-genome sequencing coupled with reverse transcription polymerase chain reaction (RT-PCR) analysis of gene expression in human retinal cells. PARTICIPANTS: A total of 141 members of 12 families with NCMD and 261 unrelated control individuals.
METHODS: Genome sequencing was performed on 8 affected individuals from 3 families affected with chromosome 6-linked NCMD (MCDR1) and 2 individuals affected with chromosome 5-linked NCMD (MCDR3). Variants observed in the MCDR1 locus with frequencies <1% in published databases were confirmed using Sanger sequencing. Confirmed variants absent from all published databases were sought in 8 additional MCDR1 families and 261 controls. The RT-PCR analysis of selected genes was performed in stem cell-derived human retinal cells. MAIN OUTCOME MEASURES: Co-segregation of rare genetic variants with disease phenotype.
RESULTS: Five sequenced individuals with MCDR1-linked NCMD shared a haplotype of 14 rare variants spanning 1 Mb of the disease-causing allele. One of these variants (V1) was absent from all published databases and all 261 controls, but was found in 5 additional NCMD kindreds. This variant lies in a DNase 1 hypersensitivity site (DHS) upstream of both the PRDM13 and CCNC genes. Sanger sequencing of 1 kb centered on V1 was performed in the remaining 4 NCMD probands, and 2 additional novel single nucleotide variants (V2 in 3 families and V3 in 1 family) were identified in the DHS within 134 bp of the location of V1. A complete duplication of the PRDM13 gene was also discovered in a single family (V4). The RT-PCR analysis of PRDM13 expression in developing retinal cells revealed marked developmental regulation. Next-generation sequencing of 2 individuals with MCDR3-linked NCMD revealed a 900-kb duplication that included the entire IRX1 gene (V5). The 5 mutations V1 to V5 segregated perfectly in the 102 affected and 39 unaffected members of the 12 NCMD families.
CONCLUSIONS: We identified 5 rare mutations, each capable of arresting human macular development. Four of these strongly implicate the involvement of PRDM13 in macular development, whereas the pathophysiologic mechanism of the fifth remains unknown but may involve the developmental dysregulation of IRX1.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26507665      PMCID: PMC4695238          DOI: 10.1016/j.ophtha.2015.10.006

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  55 in total

Review 1.  The prevalence of age-related maculopathy by geographic region and ethnicity.

Authors:  R Klein; B E Klein; K J Cruickshanks
Journal:  Prog Retin Eye Res       Date:  1999-05       Impact factor: 21.198

2.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

Review 3.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Authors:  Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge
Journal:  Ophthalmology       Date:  2007-08-06       Impact factor: 12.079

4.  Macular function testing in a German pedigree with North Carolina macular dystrophy.

Authors:  K Rohrschneider; A Blankenagel; F E Kruse; T Fendrich; H E Völcker
Journal:  Retina       Date:  1998       Impact factor: 4.256

5.  A North Carolina macular dystrophy phenotype in a Belizean family maps to the MCDR1 locus.

Authors:  M F Rabb; L Mullen; S Yelchits; N Udar; K W Small
Journal:  Am J Ophthalmol       Date:  1998-04       Impact factor: 5.258

6.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  North Carolina macular dystrophy: clinical features, genealogy, and genetic linkage analysis.

Authors:  K W Small
Journal:  Trans Am Ophthalmol Soc       Date:  1998

8.  Clinical characterization and genetic mapping of North Carolina macular dystrophy.

Authors:  Zhenglin Yang; Zongzhong Tong; Louis J Chorich; Erik Pearson; Xian Yang; Anthony Moore; David M Hunt; Kang Zhang
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

9.  Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome.

Authors:  Kirk Mykytyn; Darryl Y Nishimura; Charles C Searby; Mythreyi Shastri; Hsan-jan Yen; John S Beck; Terry Braun; Luan M Streb; Alberto S Cornier; Gerald F Cox; Anne B Fulton; Rivka Carmi; Güven Lüleci; Settara C Chandrasekharappa; Francis S Collins; Samuel G Jacobson; John R Heckenlively; Richard G Weleber; Edwin M Stone; Val C Sheffield
Journal:  Nat Genet       Date:  2002-07-15       Impact factor: 38.330

10.  Phenotype of a British North Carolina macular dystrophy family linked to chromosome 6q.

Authors:  M B Reichel; R E Kelsell; J Fan; C Y Gregory; K Evans; A T Moore; D M Hunt; F W Fitzke; A C Bird
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

View more
  28 in total

1.  Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.

Authors:  Erin R Burnight; Manav Gupta; Luke A Wiley; Kristin R Anfinson; Audrey Tran; Robinson Triboulet; Jeremy M Hoffmann; Darcey L Klaahsen; Jeaneen L Andorf; Chunhua Jiao; Elliott H Sohn; Malavika K Adur; Jason W Ross; Robert F Mullins; George Q Daley; Thorsten M Schlaeger; Edwin M Stone; Budd A Tucker
Journal:  Mol Ther       Date:  2017-06-12       Impact factor: 11.454

2.  Generation of Xeno-Free, cGMP-Compliant Patient-Specific iPSCs from Skin Biopsy.

Authors:  Luke A Wiley; Kristin R Anfinson; Cathryn M Cranston; Emily E Kaalberg; Malia M Collins; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Curr Protoc Stem Cell Biol       Date:  2017-08-14

3.  Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.

Authors:  Luke A Wiley; Erin R Burnight; Arlene V Drack; Bailey B Banach; Dalyz Ochoa; Cathryn M Cranston; Robert A Madumba; Jade S East; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Hum Gene Ther       Date:  2016-07-11       Impact factor: 5.695

4.  Benign Yellow Dot Maculopathy: A New Macular Phenotype.

Authors:  Arundhati Dev Borman; Aleksandra Rachitskaya; Martina Suzani; Robert A Sisk; Zubair M Ahmed; Graham E Holder; Valentina Cipriani; Gavin Arno; Andrew R Webster; Robert B Hufnagel; Audina Berrocal; Anthony T Moore
Journal:  Ophthalmology       Date:  2017-03-31       Impact factor: 12.079

5.  Prdm13 is required for Ebf3+ amacrine cell formation in the retina.

Authors:  Noah B Goodson; Jhenya Nahreini; Grace Randazzo; Ana Uruena; Jane E Johnson; Joseph A Brzezinski
Journal:  Dev Biol       Date:  2017-12-16       Impact factor: 3.582

6.  A Method for Sectioning and Immunohistochemical Analysis of Stem Cell-Derived 3-D Organoids.

Authors:  Luke A Wiley; David C Beebe; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Curr Protoc Stem Cell Biol       Date:  2016-05-12

7.  LRRTM4-C538Y novel gene mutation is associated with hereditary macular degeneration with novel dysfunction of ON-type bipolar cells.

Authors:  Yuichi Kawamura; Akiko Suga; Takuro Fujimaki; Kazutoshi Yoshitake; Kazushige Tsunoda; Akira Murakami; Takeshi Iwata
Journal:  J Hum Genet       Date:  2018-05-14       Impact factor: 3.172

8.  Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease.

Authors:  Edwin M Stone; Jeaneen L Andorf; S Scott Whitmore; Adam P DeLuca; Joseph C Giacalone; Luan M Streb; Terry A Braun; Robert F Mullins; Todd E Scheetz; Val C Sheffield; Budd A Tucker
Journal:  Ophthalmology       Date:  2017-05-27       Impact factor: 12.079

Review 9.  Patient derived stem cells for discovery and validation of novel pathogenic variants in inherited retinal disease.

Authors:  Nathaniel K Mullin; Andrew P Voigt; Jessica A Cooke; Laura R Bohrer; Erin R Burnight; Edwin M Stone; Robert F Mullins; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2020-10-29       Impact factor: 21.198

Review 10.  Ubiquitous Chromatin Modifiers in Congenital Retinal Diseases: Implications for Disease Modeling and Regenerative Medicine.

Authors:  Brian W Basinski; Daniel A Balikov; Michael Aksu; Qiang Li; Rajesh C Rao
Journal:  Trends Mol Med       Date:  2021-02-08       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.